{"Signatur": "CH_BGE_007", "Spider": "CH_BGE", "Sprache": "de", "Datum": "2024-03-18", "HTML": {"Datei": "CH_BGE/CH_BGE_007_BGE-150-V-210_2024-03-18.html", "URL": "https://search.bger.ch/ext/eurospider/live/de/php/clir/http/index.php?lang=de&type=highlight_simple_query&page=14&from_date=&to_date=&from_year=2024&to_year=2024&sort=relevance&insertion_date=&from_date_push=&top_subcollection_clir=bge&query_words=&part=all&de_fr=&de_it=&fr_de=&fr_it=&it_de=&it_fr=&orig=&translation=&rank=134&highlight_docid=atf%3A%2F%2F150-V-210%3Ade&number_of_ranks=177&azaclir=clir", "Checksum": "91284e1faf278f34859b4e7d2c73eda6"}, "Scrapedate": "2025-06-16", "Num": ["BGE 150 V 210", "9C_65/2023"], "Kopfzeile": [{"Sprachen": ["de"], "Text": "Bundesgericht (BGE) Band V 18.03.2024 BGE 150 V 210 (9C_65/2023)"}, {"Sprachen": ["fr"], "Text": "Tribunal f\u00e9d\u00e9ral (ATF) Volume V 18.03.2024 BGE 150 V 210 (9C_65/2023)"}, {"Sprachen": ["it"], "Text": "Tribunale federale (DTF) Volume V 18.03.2024 BGE 150 V 210 (9C_65/2023)"}], "Meta": [{"Sprachen": ["de"], "Text": "Eidgenossenschaft Bundesgericht (BGE) Band V"}, {"Sprachen": ["fr"], "Text": "Conf\u00e9deration Tribunal f\u00e9d\u00e9ral (ATF) Volume V"}, {"Sprachen": ["it"], "Text": "Confederazione Tribunale federale (DTF) Volume V"}, {"Sprachen": ["de", "fr", "it"], "Text": "III. \u00f6ffentlich-rechtlichen Abteilung"}], "Abstract": [{"Sprachen": ["de"], "Text": "Regeste\n<br>Art. 25 Abs. 1 und 2 lit. b, Art. 32 Abs. 1 Satz 1, Art. 34 Abs. 1, Art. 44 Abs. 1 Satz 1, Art. 52 Abs. 1 lit. a Ziff. 2 und lit. b KVG; Art. 63 Abs. 2 KVV; ALT II (Bearbeitungstarif) lit. D Ziff. 2 (nachfolgend: ALT II D 2); Art. 4 Abs. 1 lit. a und c HMG; Herstellungstaxe. Die in Frage stehende, in der Spitalapotheke vorgenommene Aufbereitung der Zytostatika f\u00e4llt unter die Herstellungstaxe gem\u00e4ss ALT II D 2 (\"Aseptische Zytostatika-Herstellung gem\u00e4ss guter Herstellungspraxis [GMP]\") und ist daher, zumal wirksam, zweckm\u00e4ssig und wirtschaftlich, vom obligatorischen Krankenpflegeversicherer entsprechend zu verg\u00fcten (E. 7-10)."}, {"Sprachen": ["fr"], "Text": "Regeste\n<br>Art. 25 al. 1 et 2 let. b, art. 32 al. 1, 1<sup>re</sup> phrase, art. 34 al. 1, art. 44 al. 1, 1<sup>re</sup> phrase, art. 52 al. 1 let. a ch. 2 et let. b LAMal; art. 63 al. 2 OAMal; LMT II (tarif des manipulations) let. D ch. 2 (ci-apr\u00e8s: LMT II D 2); art. 4 al. 1 let. a et c LPTh; taxe pour la fabrication. La pr\u00e9paration des cytostatiques en question, effectu\u00e9e dans la pharmacie d'un h\u00f4pital, est soumise \u00e0 la taxe de fabrication selon LMT II D 2 (\"Fabrication aseptique de cytostatique selon les bonnes pratiques de fabrication [GMP]\"); les co\u00fbts de cette prestation doivent \u00eatre rembours\u00e9s en cons\u00e9quence par l'assurance obligatoire des soins, d\u00e8s lors qu'elle est efficace, appropri\u00e9e et \u00e9conomique (consid. 7-10)."}, {"Sprachen": ["it"], "Text": "Regesto\n<br>Art. 25 cpv. 1 e 2 lett. b, art. 32 cpv. 1, prima frase, art. 34 cpv. 1, art. 44 cpv. 1, prima frase, art. 52 cpv. 1 lett. a n. 2 e lett. b LAMal; art. 63 cpv. 2 OAMal; EMT II (tariffa delle manipolazioni) lett. D n. 2 (di seguito: EMT II D 2); art. 4 cpv. 1 lett. a e c LATer; tassa per la fabbricazione. La preparazione dei farmaci citostatici in questione effettuata nella farmacia d'ospedale \u00e8 soggetta alla tassa di fabbricazione ai sensi dell'EMT II D 2 (\"Fabbricazione asettica di citostatico secondo la buona prassi di fabbricazione [GMP]\") e deve di conseguenza essere rimborsata dall'assicurazione obbligatoria delle cure medico-sanitarie, tanto pi\u00f9 che \u00e8 efficace, appropriata ed economica (consid. 7-10)."}], "ScrapyJob": "446973/47/2482", "Zeit UTC": "16.06.2025 01:41:50", "Checksum": "99fb718f973f01cc22f1c28576ba272c"}